{"id":108694,"date":"2026-02-02T12:49:29","date_gmt":"2026-02-02T11:49:29","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/orikine-bio-receives-e2-7m-in-investment-from-cdti-innovacion-together-with-two-other-investors\/"},"modified":"2026-02-02T12:49:29","modified_gmt":"2026-02-02T11:49:29","slug":"orikine-bio-receives-e2-7m-in-investment-from-cdti-innovacion-together-with-two-other-investors","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/orikine-bio-receives-e2-7m-in-investment-from-cdti-innovacion-together-with-two-other-investors\/","title":{"rendered":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors"},"content":{"rendered":"

The biotechnology company Orikine Bio<\/a>, recently established at the Barcelona Science Park, has received an investment of \u20ac2.7 million from the SICC Innvierte of CDTI Innovaci\u00f3n together with the fund managers Asabys Partners (Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA) and AdBio Partners (AFB Seed Fund II). With this capital injection, the company will continue to drive the development of a new generation of therapies for autoimmune, inflammatory and oncological diseases.<\/strong><\/p>\n

CDTI Innovaci\u00f3n, through Innvierte, has closed an investment deal in this biotechnology company together with Sabadell Asabys Health Innovation Investments II, FCR; Sabadell Asabys Health Innovation Investments 2B, SCR SA; and AFB Seed Fund II, for a total amount of \u20ac2.7 million. With this participation, CDTI Innovaci\u00f3n helps to improve people\u2019s health and well-being by promoting the development of products that accelerate patient recovery.<\/p>\n

Orikine Bio has a team made up of experts in biotechnology, immunology, protein engineering, and business development. Their main objective is to develop therapies capable of \u201creprogramming\u201d the immune system, in a similar way to how software engineers rewrite faulty code to repair computer systems.<\/p>\n

Their proprietary Foldikine\u2122 platform designs bispecific cytokines\u2014molecules that send precise, targeted instructions to immune cells in a specific, effective, and safe manner. By reprogramming these cells, they restore proper immune function and offer innovative solutions for conditions such as autoimmune diseases and chronic inflammation.<\/p>\n

With this new investment and the technological boost provided by the Foldikine\u2122 platform, Orikine Bio strengthens its growth potential and consolidates its commitment to developing innovative therapies that improve people\u2019s quality of life. The operation represents a step forward in translating scientific knowledge into high\u2011impact solutions for the healthcare system.<\/p>\n

\u00bb Access to the news:<\/strong> CDTI website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The biotechnology company Orikine Bio, recently established at the Barcelona Science Park, has received an investment of \u20ac2.7 million from the SICC Innvierte of CDTI Innovaci\u00f3n together with the fund…<\/p>\n","protected":false},"author":14,"featured_media":108690,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[375],"class_list":["post-108694","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-orikine"],"acf":[],"yoast_head":"\nOrikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T11:49:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors\",\"datePublished\":\"2026-02-02T11:49:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"keywords\":[\"Orikine\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\",\"name\":\"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"datePublished\":\"2026-02-02T11:49:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/coinversion_orikine_bio-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona","description":"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","og_locale":"en_US","og_type":"article","og_title":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona","og_description":"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.","og_url":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-02-02T11:49:29+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors","datePublished":"2026-02-02T11:49:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"},"wordCount":309,"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","keywords":["Orikine"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","url":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/","name":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","datePublished":"2026-02-02T11:49:29+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"The company will continue to drive the development of new therapies for autoimmune, inflammatory and oncological diseases.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/02\/coinversion_orikine_bio-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/orikine-bio-rep-27-me-dinversio-del-cdti-innovacio-amb-altres-dos-inversors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Orikine Bio receives \u20ac2.7M in investment from CDTI Innovaci\u00f3n together with two other investors"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/108694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=108694"}],"version-history":[{"count":0,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/108694\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/108690"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=108694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=108694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=108694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}